Abstract: According to the United States Environmental Protection Agency (USEPA), a number of drug entities and pharmaceutical formulations, generated in health care facilities, meet the definition of hazardous waste, including epinephrine, warfarin, nicotine, and seven chemotherapeutic agents. This study has been carried out to assess the hazardous pharmaceutical waste generation in one large multi-specialty hospital in Alexandria for the ultimate objective of recommending an environmentally sound management plan for this waste. Alexandria University Main Hospital was selected for the study. A checklist containing the names of the drugs that are considered hazardous upon disposal was developed. Data concerning the generation and the management of this waste were collected using 2 questionnaire forms. The study revealed that ten hazardous pharmaceuticals are generated from the hospital departments. They are Epinephrine, m-cresol, phenol, silver sulfadiazine, multi-mineral formulations containing Cr and Se, warfarin, cyclophosphamide, chlorambucil, melphalan, and daunomycin. These drugs, as well as the other pharmaceutical waste, are managed as infectious waste: collected in yellow bags, stored in the storage area for infectious waste, and transported by the Private Company responsible for solid waste management in Alexandria Governorate to treatment by shredding and autoclaving prior to ultimate landfill. Consequently, the study recommended a hazardous pharmaceutical waste management plan taking into consideration other equally hazardous drugs such as all chemotherapeutic agents, mutagenic or teratogenic substances, endocrine disruptors, and immunosuppressant drugs. Thermal destruction of all these drugs would provide the highest level of best management practice available at this time. The ash resulting has to be tested and eventually disposed in a lined hazardous waste landfill.
INTRODUCTION
In a health care facility, pharmaceutical waste is generated through a wide variety of activities, including but not limited to intravenous (IV) preparation, spills/breakage, partially used vials, syringes, and IVs, discontinued, or unused preparations, patients' personal medications, and outdated pharmaceuticals. (1) In Italy, researches have identified a group of pharmaceuticals (ofloxacin, furosemide, atenolol, hydrochlorothiazide, carbamazepine, ibuprofen, spiramycin, bezafibrate, erythromycin, lincomycin and clarithromycin) in the aquatic environment and also in samples of ground and drinking water. (2, 3) Another one-year monitoring study was viability of eggs, and male sex reversal. (6) (7) (8) Concentrations at which these effects were observed were lower than concentrations detected in surface waters sampled. (9) Second, drug residues that make their way to drinking water sources could pose the potential for significant rise in antibiotic (9) In Egypt, discharge of drugs to sewerage system does not violate water regulations as drug residues are not covered by regulations for water quality. (12) In addition, law 4/94 that governs hazardous waste management including health care waste does not distinguish hazardous pharmaceutical waste that has to be incinerated, from hospital infectious waste that can be either incinerated or autoclaved. (13) Accordingly, this study has been carried out to assess the hazardous pharmaceutical waste generation in one large multi-specialty hospital in Alexandria for the ultimate objective of recommending an environmentally sound management plan for this waste.
Objectives of the study:
1. Developing a checklist with the names of the drugs that are considered hazardous upon disposal.
2. Determination of the source of these hazardous pharmaceutical wastes within a multi-specialty hospital.
3. Study of the management of these hazardous pharmaceutical wastes within the surveyed hospital.
Recommendation of an
environmentally sound management plan for pharmaceutical waste generated in health care facilities.
MATERIAL AND METHODS

Study setting: Alexandria University
Main Hospital.
2. The checklist was developed using USEPA guidelines. (1, 9, 14) 3. Data collection: Two questionnaire forms were designed:
a) The first was directed to each department in the hospital asking about the generation of any drug waste listed among the pre-developed checklist.
b) The second questionnaire was directed to the Head of the Nursing Staff asking about the system adopted for pharmaceutical waste management.
RESULTS AND DISCUSSION
a) Hazardous pharmaceutical waste checklist: and (2) No more than 3% by weight remains. If both of these criteria are not met, the container must be managed as hazardous waste. In addition, any residues removed from the empty container must be managed as hazardous waste. (9) Ignitability applies to formulations that have a flash point less than 60°C (e.g., rubbing alcohol, some topical preparations)
or that are strong oxidizers such as amyl Results of the survey revealed that among the 35 hazardous pharmaceutical wastes stated in Table 1 , only 10 are generated in the surveyed Hospital (Table   2 ). Epinephrine in the form of adrenaline tartarate of 1mg/ml concentration is by far the most common hazardous drug waste generated (generated in 22 sites/30 under study). This was in accordance to Pines E final disposal. (14) • No special records are kept tracking the generation of pharmaceutical waste (point of generation, names, quantities).
• No pharmaceutical waste is dropped down the sewerage system.
• 1. An interdepartmental, multidisciplinary team should be formed in the hospital to be accountable for the management of pharmaceutical waste.
A comprehensive drug inventory has to
be performed in order to determine which ones must be managed as hazardous waste (Referring to Table   1 ).
Best management practices encourage
managing some other drugs as hazardous waste when discarded: • Drugs with LD50s less than or equal to 50 mg/kg Such criteria include mutagenicity, carcinogenicity, teratogenicity, genotoxicity, or reproductive toxicity.
• Endocrine Disruptors (e.g., contraceptives, oxytocics)
• Immuno-suppressants.
• Vitamin and mineral preparations with potential toxicity due to their content of chromium, selenium, or cadmium. (1) 4. Once the pharmaceuticals have been 
